Oric Pharmaceuticals (ORIC) Receives a Buy from Evercore ISI
I'm PortAI, I can summarize articles.
Evercore ISI analyst Cory Kasimov maintained a Buy rating on Oric Pharmaceuticals with a $25.00 price target. The stock closed at $8.04, suggesting significant upside potential. Kasimov is a 5-star analyst with a 16.2% average return. The consensus rating for Oric is Strong Buy, with a $19.33 average price target, indicating a 140.42% upside. Wedbush also maintained a Buy rating with a $20.00 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments